Therapy with foscarnet is associated with acute renal failure. Prior studies have emphasized foscarnet's proximal tubular toxicity, but there have been isolated reports of foscarnet-induced nephrogenic diabetes insipidus. As a phosphate analog, foscarnet is a competitive inhibitor of NaPO 4 cotransport. However, foscarnet's effect on antidiuretic hormone (ADH)-induced transport has not been previously investigated. We studied foscarnet's modulation of transport in the toad urinary bladder. Foscarnet at 10 M to 10 mM did not alter basal water or urea flux. Urea transport induced by a maximal dose of ADH (24 mIU/ml) was inhibited by 0.1 to 5.0 mM foscarnet. In tissues challenged with 0.5 to 1.0 mIU of ADH per ml, 1.0 to 10 mM foscarnet increased water flow but did not alter urea flux. Foscarnet also increased water flow induced by 1.0 to 10 M forskolin. In tissues pretreated with 10 M naproxen, foscarnet did not alter water flow induced by 0.5 to 1.0 mIU of ADH per ml or forskolin. These results indicate that foscarnet stimulates water flow induced by 0.5 to 1.0 mIU of ADH per ml at a site proximal to that of the generation of cyclic AMP and inhibits urea flux induced by a maximal dose of ADH at a separate site. In humans, foscarnet nephrotoxicity is likely not limited to the proximal nephron, but extends to the collecting duct. Patients receiving foscarnet should be closely monitored for disorders of urinary concentration.
Foscarnet (phosphonoformic acid-trisodium phosphonoformate) is a pyrophosphate analog used commonly in the treatment of human cytomegalovirus infection (14, 24, 36) . It inhibits herpes virus DNA polymerase (4, 7, 26, 27) , influenza virus RNA polymerase (22) , and retroviral reverse transcriptase (9, 16, 25, 28) . Foscarnet directly inhibits eucaryotic NaPO 4 (17, 21, 23, 29) and NaSO 4 cotransport (1) . Foscarnet also alters the number of membrane NaPO 4 cotransporters (19, 20) .
The drug is eliminated unchanged by the kidney, and nephrotoxicity is the major side effect of treatment (5) . Prior investigators have emphasized foscarnet's toxicity for the proximal nephron. Intraglomerular capillary crystal deposition (2) and necrosis of the proximal tubular epithelium may occur, but they appear preventable with prehydration with normal saline (6) . Electrolyte disturbances including hypercalcemia, hypocalcemia (15) , hypokalemia, hypomagnesemia (11) , hyperphosphatemia, and hypophosphatemia are well documented (3) . Foscarnet may form complexes with ionized calcium (15) . Cultured proximal tubule cells have recently been used as an experimental model for foscarnet toxicity (35) .
Farese and others have reported the development of nephrogenic diabetes insipidus in association with therapy with foscarnet (3, 8) . This observation may reflect the extension of toxicity to the distal nephron and collecting duct. However, the loss of the medullary gradient associated with enhanced delivery of water and electrolytes related to foscarnet's proximal tubular toxicity might produce a similar effect. To investigate whether foscarnet directly alters vasopressin-mediated transport, we studied the toad urinary bladder, a well-characterized amphibian analog of the mammalian collecting duct used in the analysis of agents implicated in the development of nephrogenic diabetes insipidus (32) . 
MATERIALS AND METHODS
Dominican female toads (Bufo marinus; National Reagents, Bridgeport, Conn.) were double pithed. Their paired hemibladders were tied on glass tubing so that they were fully distended at a volume of 8 ml and were washed with phosphate-buffered Ringer solution (120 mM Na, 4 mM K, 0.5 mM Ca, 116 mM Cl, 5 mM phosphate [pH 7.4], 230 mosmol per kg of H 2 O) as previously reported in detail (12, 30) . The tissues were maintained at room temperature and transferred to 50-ml beakers containing 35 ml of phosphate-buffered Ringer solution bubbled with air. The mucosal bathing medium was one-fifth isotonic phosphatebuffered Ringer solution.
Water flow was measured gravimetrically at 15-min intervals. To analyze urea transport, tracer quantities of 14 C urea were added to the mucosal bath. At 15-min intervals, serial serosal and mucosal bath samples were pipetted into scintillant and counted.
Foscarnet (kindly supplied by Astra Pharmaceuticals, Westboro, Mass.) was added to the serosal or mucosal bath of experimental tissues at time zero, and basal transport was measured. The antidiuretic hormone (ADH) arginine vasopressin (Sigma V 5501) at 0.5 to 24 mIU/ml, 1 to 10 M forskolin (Calbiochem, La Jolla, Calif.), 0.04 to 0.2 mM 8-Br-cAMP (8-bromoadenosine 3Ј:5Ј-cyclic monophosphate [Sigma B 7880]), or 0.8 to 4 mM IBMX (1-methyl-3-isobutylxanthine [Sigma I 5879]) was added at 30 min to the serosal bathing media of all tissues. For experiments calling for the inhibition of prostaglandin synthesis, tissues were pretreated with 10 M naproxen (Sigma M 1275) for 45 min, and the experiments were performed with the continued presence of naproxen. For studies requiring prolonged foscarnet pretreatment or prolonged ADH challenge, tissues were maintained in amphibian culture medium (GIBCO no. 350-1835) diluted 1:4 with phosphate-buffered Ringer solution as previously reported (13) .
Data were analyzed for significance by Student's t test for paired data (33) .
RESULTS

Experiments with foscarnet in the serosal bath. (i) Experiments with ADH.
When it was added to the serosal bath, 10 M to 5.0 mM foscarnet did not alter water or urea transport in the absence of ADH. Foscarnet at 10 m to 1.0 mM did not alter water transport induced with the maximal dose of ADH (23 mIU/ml). Foscarnet at 5.0 mM slightly but significantly increased water transport induced with the maximal dose of ADH. In contrast, urea permeation induced with the maximal dose of ADH was significantly inhibited with 100 M to 5.0 mM foscarnet (Table 1) .
In experiments in which there was 4 to 24 h of pretreatment with 1.0 mM foscarnet, basal water and urea transport were unchanged. Foscarnet did not alter water transport induced with 23 mIU of ADH per ml but did significantly inhibit ADHinduced urea permeation with 4 h of preincubation (Table 2) . In experiments in which there was a 4-h continuous challenge with 23 mIU of ADH per ml, 1.0 mM foscarnet did not alter water permeation (Fig. 1) .
In experiments in which a submaximal dose of ADH (1 mIU/ml) was used, 1.0 to 10 mM foscarnet significantly increased ADH-induced water permeation (Fig. 2) . Urea permeation was not altered.
(ii) Experiments with forskolin. In an attempt to localize the site of foscarnet action, experiments with agents known to enhance water and urea permeation distal to the binding of vasopressin to its receptor were performed. In studies with 1.0 to 10 M forskolin, water permeation was significantly enhanced with 1.0 to 5.0 mM foscarnet (Fig. 3) . In these experiments, urea permeation was not significantly altered.
(iii) Experiments with 8-Br-cAMP and IBMX. Foscarnet (1.0 mM) did not alter water or urea transport induced with 0.8 to 4.0 mM IBMX or 0.04 to 0.20 mM 8-Br-cAMP (Table 3) .
(iv) Experiments with naproxen. In tissues pretreated with naproxen, foscarnet did not alter water and urea transport 
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induced with 0.5 to 24 mIU of ADH per ml or 1.0 to 10 M forskolin (Table 4) . Experiments with foscarnet in the mucosal bath with ADH and forskolin. When it was added to the mucosal bath, foscarnet (0.1 to 9.1 mM) did not alter basal water or urea transport or transport induced with 1.0 to 24 mIU of ADH per ml or 1.0 to 10 M forskolin (Table 5) .
DISCUSSION
The dose of foscarnet causing transport alterations in our studies is within an order of magnitude of drug concentrations measured in clinical practice. Seidel and colleagues achieved foscarnet levels of 0.5 to 1 mM in three patients (31) . In their series of 11 patients, Taburet and associates measured foscarnet levels of 0.3 to 0.9 mM (34). Foscarnet concentrations of 0.6 to 6.0 mM demonstrated toxicity for cultured proximal tubule cells, whereas lower concentrations were without effect (35) . In our experiments, the threshold foscarnet concentration for the inhibition of ADH-induced urea transport was 0.1 mM.
ADH increases both water and urea transport in the amphibian urinary bladder and mammalian collecting duct. However, separate vasopressin-induced water channels and urea transporters have been characterized (10, 37) , and in this context, foscarnet's disparate effects on water flow and urea transport are not surprising.
Foscarnet's interaction with ADH-responsive epithelia has not been previously investigated. Our data demonstrate that foscarnet alters ADH-mediated water and urea transport in opposite directions. When it is added to serosal bathing media, foscarnet significantly enhances water flow induced with forskolin and submaximal concentrations of ADH and inhibits urea transport induced with a maximal dose of ADH. These distinct observations cannot be explained by a single effect. In particular, the failure of foscarnet to alter transport induced with 8-Br-cAMP and IBMX suggests that foscarnet stimulates water flow at a site proximal to that of the generation of cyclic AMP (cAMP). Foscarnet does not affect transport when it is present in mucosal bathing media. This is also consistent with the sites of foscarnet action being near the basolateral membrane; however, this lack of effect may also be secondary to mucosal permeability barriers for foscarnet. Transport alterations are not demonstrable with naproxen pretreatment, indicating that foscarnet's effects may be related in part to such naproxen-inhibitable metabolites as prostaglandins. It is interesting that prostaglandins are known to regulate ADH-induced transport at multiple sites (30) and that the intracellular calcium concentration is an important modulator of prostaglandin synthesis (18) . Foscarnet has previously been shown to chelate calcium (15) , and calcium concentration is an important regulator of ADH action (18) . It is possible that in patients receiving foscarnet, concurrent treatment with such nonsteroidal agents as naproxen could prevent the development of nephrogenic diabetes insipidus. However, potentiation of other nephrotoxic actions of foscarnet might then occur.
In summary, our results indicate that foscarnet treatment stimulates water flow induced with 0.5 to 1 mIU of ADH per 
